ATE250409T1 - Druckdosierinhalator und pharmazeutische aerosol formulierungen enthaltend einen beta-agonisten - Google Patents

Druckdosierinhalator und pharmazeutische aerosol formulierungen enthaltend einen beta-agonisten

Info

Publication number
ATE250409T1
ATE250409T1 AT99931837T AT99931837T ATE250409T1 AT E250409 T1 ATE250409 T1 AT E250409T1 AT 99931837 T AT99931837 T AT 99931837T AT 99931837 T AT99931837 T AT 99931837T AT E250409 T1 ATE250409 T1 AT E250409T1
Authority
AT
Austria
Prior art keywords
formulations containing
aerosol formulations
pharmaceutical aerosol
beta agonist
pressure inhaler
Prior art date
Application number
AT99931837T
Other languages
English (en)
Inventor
Frank E Blondino
Michael Brucato
Maria W Buenafe
Original Assignee
Ivax Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ivax Research Inc filed Critical Ivax Research Inc
Application granted granted Critical
Publication of ATE250409T1 publication Critical patent/ATE250409T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/124—Aerosols; Foams characterised by the propellant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT99931837T 1998-06-19 1999-06-18 Druckdosierinhalator und pharmazeutische aerosol formulierungen enthaltend einen beta-agonisten ATE250409T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/099,779 US6451285B2 (en) 1998-06-19 1998-06-19 Suspension aerosol formulations containing formoterol fumarate and a fluoroalkane propellant
PCT/US1999/013863 WO1999065460A2 (en) 1998-06-19 1999-06-18 Pressurized metered dose inhalers and pharmaceutical aerosol formulations comprising a beta-agonist

Publications (1)

Publication Number Publication Date
ATE250409T1 true ATE250409T1 (de) 2003-10-15

Family

ID=22276581

Family Applications (2)

Application Number Title Priority Date Filing Date
AT99931837T ATE250409T1 (de) 1998-06-19 1999-06-18 Druckdosierinhalator und pharmazeutische aerosol formulierungen enthaltend einen beta-agonisten
AT02026980T ATE260093T1 (de) 1998-06-19 1999-06-18 Aerosoldruckdosiergeräte und aerosolarzneizusammensetzungen

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT02026980T ATE260093T1 (de) 1998-06-19 1999-06-18 Aerosoldruckdosiergeräte und aerosolarzneizusammensetzungen

Country Status (23)

Country Link
US (2) US6451285B2 (de)
EP (2) EP1306082B1 (de)
JP (1) JP2002518100A (de)
KR (1) KR20010053025A (de)
CN (2) CN1154477C (de)
AR (1) AR018891A1 (de)
AT (2) ATE250409T1 (de)
AU (1) AU762927B2 (de)
BR (1) BR9912170A (de)
CA (1) CA2335303A1 (de)
CO (1) CO5031245A1 (de)
DE (2) DE69911602T2 (de)
DK (2) DK1085856T3 (de)
ES (2) ES2205848T3 (de)
HU (1) HUP0102468A3 (de)
IL (1) IL140340A0 (de)
NO (1) NO20006466L (de)
PL (1) PL345399A1 (de)
PT (2) PT1306082E (de)
RU (1) RU2214230C2 (de)
SK (1) SK19442000A3 (de)
WO (1) WO1999065460A2 (de)
ZA (1) ZA200007455B (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9616237D0 (en) 1996-08-01 1996-09-11 Norton Healthcare Ltd Aerosol formulations
US20010031244A1 (en) * 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
US6451285B2 (en) * 1998-06-19 2002-09-17 Baker Norton Pharmaceuticals, Inc. Suspension aerosol formulations containing formoterol fumarate and a fluoroalkane propellant
DZ2947A1 (fr) 1998-11-25 2004-03-15 Chiesi Farma Spa Inhalateur à compteur de dose sous pression.
US6315985B1 (en) * 1999-06-18 2001-11-13 3M Innovative Properties Company C-17/21 OH 20-ketosteroid solution aerosol products with enhanced chemical stability
IT1313553B1 (it) 1999-07-23 2002-09-09 Chiesi Farma Spa Formulazioni ottimizzate costituite da soluzioni di steroidi dasomministrare per inalazione.
IT1317720B1 (it) * 2000-01-07 2003-07-15 Chiesi Farma Spa Dispositivo per la somministrazione di aerosol dosati pressurizzati inpropellenti idrofluoroalcani.
IT1317846B1 (it) * 2000-02-22 2003-07-15 Chiesi Farma Spa Formulazioni contenenti un farmaco anticolinergico per il trattamentodella broncopneumopatia cronica ostruttiva.
IT1318514B1 (it) * 2000-05-12 2003-08-27 Chiesi Farma Spa Formulazioni contenenti un farmaco glucocorticosteroide per iltrattamento di patologie broncopolmonari.
US20060257324A1 (en) 2000-05-22 2006-11-16 Chiesi Farmaceutici S.P.A. Pharmaceutical solution formulations for pressurised metered dose inhalers
EE05167B1 (et) 2000-05-22 2009-06-15 Chiesi Farmaceutici S.P.A. Stabiilsed farmatseutilised lahuspreparaadid survestatud doseerivatele inhalaatoritele
US20030072717A1 (en) * 2001-02-23 2003-04-17 Vapotronics, Inc. Inhalation device having an optimized air flow path
CN100496608C (zh) * 2001-03-30 2009-06-10 洁垢技术有限公司 药用气溶胶制剂
ES2222294T3 (es) * 2001-07-02 2005-02-01 Chiesi Farmaceutici S.P.A. Formulacion optimizada de tobramicina para administracion en forma de aerosol.
US20030178022A1 (en) * 2001-12-21 2003-09-25 Chiesi Farmaceutici S.P.A. Pressurized metered dose inhaler (PMDI) actuators and medicinal aerosol solution formulation products comprising therse actuators
DE10205087A1 (de) * 2002-02-07 2003-08-21 Pharmatech Gmbh Cyclodextrine als Suspensionsstabilisatoren in druckverflüssigten Treibmitteln
ME00077B (me) * 2002-03-01 2010-06-10 Chiesi Farm Spa Formoterol najfiniji preparat
GB0207899D0 (en) * 2002-04-05 2002-05-15 3M Innovative Properties Co Formoterol and cielesonide aerosol formulations
US20050158248A1 (en) * 2002-08-21 2005-07-21 Xian-Ming Zeng Method of preparing dry powder inhalation compositions
GB0219511D0 (en) * 2002-08-21 2002-10-02 Norton Healthcare Ltd Method of preparing dry powder inhalation compositions
US8273331B2 (en) * 2002-08-21 2012-09-25 Norton Healthcare Ltd. Inhalation compositions
US6979580B2 (en) 2002-12-09 2005-12-27 Progressant Technologies, Inc. Process for controlling performance characteristics of a negative differential resistance (NDR) device
GB0323684D0 (en) 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
GB0323685D0 (en) * 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
EP1595531A1 (de) 2004-05-13 2005-11-16 CHIESI FARMACEUTICI S.p.A. Stabile Arzneimittellösung für Druckdosierinhalatoren
WO2007008427A2 (en) * 2005-07-08 2007-01-18 Xemplar Pharmaceuticals, Llc Aerosol compositions and methods
US8367734B1 (en) 2005-08-11 2013-02-05 Amphastar Pharmaceuticals Inc. Stable epinephrine suspension formulation with high inhalation delivery efficiency
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
PT2435025T (pt) * 2009-05-29 2016-11-11 Pearl Therapeutics Inc Administração, por via respiratória, de agentes activos
GB0918149D0 (en) 2009-10-16 2009-12-02 Jagotec Ag Improved medicinal aerosol formulation
US20120272951A1 (en) 2009-12-16 2012-11-01 3M Innovative Properties Company Formulations and methods for controlling mdi particle size delivery
GB201108039D0 (en) 2011-05-13 2011-06-29 Mexichem Amanco Holding Sa Compositions
GB201117621D0 (en) 2011-10-12 2011-11-23 Mexichem Amanco Holding Sa Compositions
GB201117619D0 (en) 2011-10-12 2011-11-23 Mexichem Amanco Holding Sa Compositions
JP6454323B2 (ja) 2013-03-15 2019-01-16 パール セラピューティクス，インコーポレイテッド 粒子状結晶性材料のコンディショニングのための方法及びシステム
GB201306984D0 (en) 2013-04-17 2013-05-29 Mexichem Amanco Holding Sa Composition
CN112472689B (zh) 2015-12-04 2023-01-17 墨西哥氟石股份公司 药物组合物
EP3515425B1 (de) 2016-09-19 2021-06-09 Mexichem Fluor S.A. de C.V. Pharmazeutische zusammensetzung enthaltend salmeterol
JP6781829B2 (ja) 2016-09-19 2020-11-04 メキシケム フロー エセ・ア・デ・セ・ヴェ 医薬組成物
CN113288869A (zh) 2016-09-19 2021-08-24 墨西哥氟石股份公司 药物组合物
CN109464429B (zh) * 2018-12-13 2021-04-27 上海方予健康医药科技有限公司 一种吸入压力定量气雾剂药物组合物及其制备方法

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE556587A (de) 1957-01-31 1957-04-11
BE786200A (fr) * 1971-07-13 1973-01-12 Boehringer Sohn Ingelheim Traitement par inhalation de maladies bronchiques
NL7708731A (nl) 1976-08-13 1978-02-15 Montedison Spa Werkwijze voor de bereiding van nieuwe drijf- middelsamenstellingen voor aerosolen.
CA1178889A (en) * 1980-08-28 1984-12-04 Kenneth S. Su Intranasal formulation
US5225183A (en) * 1988-12-06 1993-07-06 Riker Laboratories, Inc. Medicinal aerosol formulations
US5766573A (en) * 1988-12-06 1998-06-16 Riker Laboratories, Inc. Medicinal aerosol formulations
IL97065A (en) 1990-02-02 1994-01-25 Fisons Plc Repellent preparations for aerosol
RU2098082C1 (ru) * 1990-06-28 1997-12-10 Глэксо Инк. Аэрозольная лекарственная композиция для ингаляций (варианты)
JP2854974B2 (ja) 1990-06-29 1999-02-10 フアイソンズ・ピーエルシー 加圧エアロゾル組成物
ATE114112T1 (de) 1990-10-18 1994-12-15 Minnesota Mining & Mfg Aerosolzubereitung, die beclometason 17,21- dipropionat enthält.
MX9203481A (es) 1990-10-18 1992-07-01 Minnesota Mining & Mfg Formulaciones.
US5190029A (en) 1991-02-14 1993-03-02 Virginia Commonwealth University Formulation for delivery of drugs by metered dose inhalers with reduced or no chlorofluorocarbon content
EP0504112A3 (en) 1991-03-14 1993-04-21 Ciba-Geigy Ag Pharmaceutical aerosol formulations
WO1992022286A1 (en) 1991-06-12 1992-12-23 Minnesota Mining And Manufacturing Company Albuterol sulfate suspension aerosol formulations
DE4123663A1 (de) 1991-07-17 1993-01-21 Schwabe Willmar Gmbh & Co Aerosol-zubereitung und verwendung eines treibmittels dafuer
IL103238A (en) * 1991-09-25 1995-07-31 Fisons Plc Pressurised aerosol compositions
US5736124A (en) * 1991-12-12 1998-04-07 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicament
NZ246046A (en) * 1991-12-12 1995-12-21 Glaxo Group Ltd Aerosol comprising a particulate medicament in a fluorocarbon or chlorofluorohydrocarbon and a polar cosolvent
DK0717987T3 (da) 1991-12-18 2001-11-12 Minnesota Mining & Mfg Suspension-aerosol-formuleringer
CA2123909C (en) 1991-12-18 2002-10-01 Christer Carl Gustav Carling New combination of formoterol and budesonide
DE59206234D1 (de) 1991-12-31 1996-06-13 Hoechst Ag Medizinische Aerosolformulierung
US5833950A (en) * 1992-07-31 1998-11-10 Glaxo Group Limited Aerosol formulations containing beclomethasone dipropionate-1, 1, 1, 2-tetrafluoroethane solvate
ES2129117T3 (es) * 1992-12-09 1999-06-01 Boehringer Ingelheim Pharma Formulaciones en disolucion en forma de aerosol medicinales estabilizadas.
US5492688A (en) 1993-04-28 1996-02-20 The Center For Innovative Technology Metered dose inhaler fomulations which include the ozone-friendly propellant HFC 134a and a pharmaceutically acceptable suspending, solubilizing, wetting, emulsifying or lubricating agent
US5508023A (en) 1994-04-11 1996-04-16 The Center For Innovative Technology Pharmaceutically acceptable agents for solubilizing, wetting, emulsifying, or lubricating in metered dose inhaler formulations which use HFC-227 propellant
JP4155594B2 (ja) 1994-12-22 2008-09-24 アストラゼネカ・アクチエボラーグ エアゾール製剤
DE4446891A1 (de) * 1994-12-27 1996-07-04 Falk Pharma Gmbh Stabile wäßrige Budesonid-Lösung
GB9612297D0 (en) 1996-06-11 1996-08-14 Minnesota Mining & Mfg Medicinal aerosol formulations
GB9616237D0 (en) * 1996-08-01 1996-09-11 Norton Healthcare Ltd Aerosol formulations
US6039932A (en) * 1996-09-27 2000-03-21 3M Innovative Properties Company Medicinal inhalation aerosol formulations containing budesonide
SE9603669D0 (sv) 1996-10-08 1996-10-08 Astra Ab New combination
WO1998024420A1 (en) 1996-12-04 1998-06-11 Bioglan Ireland (R & D) Limited Pharmaceutical compositions and devices for their administration
US6451285B2 (en) * 1998-06-19 2002-09-17 Baker Norton Pharmaceuticals, Inc. Suspension aerosol formulations containing formoterol fumarate and a fluoroalkane propellant
US6004537A (en) * 1998-12-18 1999-12-21 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol

Also Published As

Publication number Publication date
EP1085856B1 (de) 2003-09-24
EP1085856A2 (de) 2001-03-28
DE69915144D1 (de) 2004-04-01
AR018891A1 (es) 2001-12-12
CN1154477C (zh) 2004-06-23
BR9912170A (pt) 2001-10-23
US20020018753A1 (en) 2002-02-14
ZA200007455B (en) 2002-06-13
ES2205848T3 (es) 2004-05-01
AU762927B2 (en) 2003-07-10
US6451285B2 (en) 2002-09-17
DE69911602T2 (de) 2004-07-01
PL345399A1 (en) 2001-12-17
CN1522692A (zh) 2004-08-25
ES2215153T3 (es) 2004-10-01
HUP0102468A2 (hu) 2002-03-28
EP1306082B1 (de) 2004-02-25
US20030077230A1 (en) 2003-04-24
KR20010053025A (ko) 2001-06-25
PT1085856E (pt) 2004-01-30
ATE260093T1 (de) 2004-03-15
NO20006466L (no) 2001-02-16
WO1999065460A2 (en) 1999-12-23
WO1999065460A3 (en) 2000-04-27
NO20006466D0 (no) 2000-12-18
CO5031245A1 (es) 2001-04-27
IL140340A0 (en) 2002-02-10
HUP0102468A3 (en) 2002-12-28
RU2214230C2 (ru) 2003-10-20
JP2002518100A (ja) 2002-06-25
CN1310611A (zh) 2001-08-29
AU4825999A (en) 2000-01-05
CA2335303A1 (en) 1999-12-23
DE69911602D1 (de) 2003-10-30
DK1306082T3 (da) 2004-06-01
EP1306082A1 (de) 2003-05-02
DK1085856T3 (da) 2003-12-08
DE69915144T2 (de) 2004-12-09
SK19442000A3 (sk) 2001-09-11
PT1306082E (pt) 2004-05-31

Similar Documents

Publication Publication Date Title
DE69911602D1 (de) Druckdosierinhalator und pharmazeutische aerosol formulierungen enthaltend einen beta-agonisten
DE69904312D1 (de) Pharmazeutische aerosolformulierung
DE69912781T2 (de) Zwei oder mehrere wirkstoffe enthaltende pharmazeutische aerosolformulierungen
PL348809A1 (en) Pharmaceutical aerosol formulations containing fluoroalkanes, budesonide and formoterol
DE69807420D1 (de) Pharmazeutische aerosolzusammensetzung
EE04451B1 (et) Pulberinhalaatori kapsel farmatseutiliste preparaatide mahutamiseks
DE69942896D1 (de) Druckdosierinhalatoren
NO307864B1 (no) Farmasøytisk aerosolformulering, boks og doseringsinhalator
NL300393I1 (en) Stable pharmaceutical solution formulations for pressurised metered dose inhalers
DK0883415T3 (da) Inhalator til pulverformigt medikament
ATE236617T1 (de) Aerosol-arzneiformulierungen
DK0934057T3 (da) Medicinske aerosolformuleringer med formoterol
DE60037816D1 (de) Pharmazeutische formulierung enthaltend megalatran und dessen pro-pharmaka
HUP0200066A2 (hu) Fluoralkánokat és budeszonidot tartalmazó aeroszol formájú gyógyszerkészítmények
NO20026055D0 (no) Farmasöytisk komponent omfattende human paratyroidhormon og farmasöytisk komponent for nasal administrering inneholdende komponentene
IL160886A0 (en) Nicotine containing pharmaceutical formulations and use thereof
GB0024326D0 (en) Composition containing a herbal medicinal substance and a pharmaceutical drug

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1085856

Country of ref document: EP

REN Ceased due to non-payment of the annual fee